tbuckley/cabot-search huggingface dataset:
1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
Authors: B.T. Li, D. Planchard, K. Goto, E.F. Smit, J. De Langen, Y. Goto, K. Ninomiya, T. Kubo, M. Pérol, E. Felip, H. Hayashi, K. Nakagawa, J. Shimizu, M. Nagasaka, K.M.C. Pereira, A. Taguchi, A. Ali, M. Karnoub, R. Yonemochi, P.A. Jänne
Journal: Annals of Oncology (2023)
1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Authors: L. Zhang, Y. Ma, Y. Zhao, W.F. Fang, H. Zhao, Y. Huang, Y. Yang, X. Hou, Z. Wen, S. Zhang, J. Wang, S. Xiao, H. Wang, H. Zhu, M.S. Olivo, Y. Zhu
Journal: Annals of Oncology (2023)
1238P Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Authors: D. Lin, Y. Xi, H. Meng, Q. Feng, S. Lian, N. Gao, J. Guo, X. Yang, S. Deng, M. Li, F. Gai, C. Zhu
Journal: Annals of Oncology (2023)
923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head &amp; neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Authors: C. Le Tourneau, F. Ghiringhelli, E.B. Saada, R. Chaltiel, D. Vansteene, X. Durando, B. You, C. Borel, F. Bigot, C. Abdeddaim, G. Marret, E. Jeannot, E. Guerini Rocco, G. Frige, N. Servant, C. Dupain, M. Kamal, F. Legrand, M. Jimenez, T. Filleron
Journal: Annals of Oncology (2023)
1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Authors: X. Le, J.P. Robichaux, M.B. Nilsson, V. Ramaswamy, A. Ravichandran, J. Wu, Y.Y. Elamin, L. Hong, H. Udagawa, M. Socinski, G. Bhat, F. Lebel, S. Vincent, V. Bunn, Z. Su, J. Lawson, J. Cross, J. Heymach
Journal: Annals of Oncology (2023)
869P Utilizing H&amp;E images and digital pathology to predict response to buparlisib in SCCHN
Authors: D. Soulieres, J. Lucas, A. Desilets, O. Matcovitch-Natan, A. Bart, A. Laniado, A. Gutwillig, N. He, K. Dreyer, S. Rosen Zvi, Z. Rachmiel, J. Kaplan Kerner, H. Yehezkeli, T. Tang, L.E. Birgerson, S. Lu, J. Lorch, L.F.L. Licitra
Journal: Annals of Oncology (2023)
1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
Authors: B. Besse, A. Italiano, S. Cousin, G. Ruiter, E. Felip, E. Castanon Alvarez, S.S. Ramalingam, C.D. Rolfo, D.R. Spigel, D. Andrew, S. Cho, T. Collins, A. Hansen, G. Hawkins, R. Kurek, N. Ceaicovscaia, M. Petruzzelli, E.J. Dean, A. Sacher
Journal: Annals of Oncology (2023)
1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
Authors: M.L. Johnson, P.A. Jänne, Y. Goto, K. Yoh, S-H. Lee, L. Paz-Ares, B. Besse, S. Novello, H. Hayashi, D-W. Kim, T. John, S.C-H. Kao, E. Felip, J.C-H. Yang, M. Reck, Q. Dong, A. Sporchia, D.W. Sternberg, H.A. Yu
Journal: Annals of Oncology (2023)
1408P Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Authors: L. Masfarre Pinto, A.S.D.F.M. Parreira, N. Castro Unanua, P. Rocha, I. Morilla Ruiz, L. Teijeira Sanchez, S. Clave, N. Navarro Gorro, R. Bach Mora, I. Sánchez, M.A. Galindo Campos, A. Taus Garcia, A. Azkárate Martínez, R. Marse Fabregat, B. Bellosillo Paricio, H. Arasanz, M. Martínez Aguillo, E. Arriola
Journal: Annals of Oncology (2023)
LBA103 ICRA: Efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1
Authors: S.M.H. Einerhand, J. van Dorp, J. de Feijter, A. Daletzakis, S. Oosting, C. Bruijnen, B.B. Suelmann, M.S. van der Heijden
Journal: Annals of Oncology (2023)
1324MO CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis
Authors: R.A. Soo, B.C. Cho, J-H. Kim, M-J. Ahn, K.H. Lee, A. Zimina, S. Orlov, I. Bondarenko, Y-G. Lee, L. Yueh Ni, S.S. Lee, K.H. Lee, Y.K. Pang, C.H. Fong, J.H. Kang, C.S. Lim, P. Danchaivijitr, H. Lee, S. Park, I. Cicin
Journal: Annals of Oncology (2023)
780P Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Authors: H. Fiegl, D. Reimer, S. Schnaiter, K. Leitner, K. Wimmer, E. Schamschula, K. Steger, C. Marth, A.G. Zeimet
Journal: Annals of Oncology (2023)
864P Serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery
Authors: G. Marret, C. Lamy, S. Vacher, L. Ahmanache, M. Séné, J. Klijanienko, C. Martinat, M. Halladjian, T. Bronzini, C. Balsat, S. Sauvage, E. Martin, G. Rougier, A. Dubray Vautrin, O. Choussy, J. Masliah-Planchon, N. Servant, I. Bieche, C. Le Tourneau, M. Kamal
Journal: Annals of Oncology (2023)
1322MO Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study
Authors: W.K. Liu, B. Ding, S. Hessey, C. Martinez Ruiz, J. Kittel, C. Lombardelli, H. Lee, C. Veiga, C. Richard, A. Huebner, A. Hackshaw, C.Z. Abbosh, G. Royle, A.M. Frankell, C. Swanton, M. Jamal-Hanjani
Journal: Annals of Oncology (2023)
1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Authors: A. Curioni-Fontecedro, L. Holer, M. Frueh, S. Weindler, D. König, A. Addeo, C. Britschgi, A. Rigutto, C. Waibel, A. Bettini, F.W.F. Cerciello, S. Hiltbrunner, D.L. Nguyen, C. Zellweger, J. Musilova, R.A.F. von Moos, M. Joerger
Journal: Annals of Oncology (2023)
1331P Resistance mechanisms in EGFR-mutated advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with first-line osimertinib (osi) and monitoring plasma mutational load: Preliminary results of REM study
Authors: L. Bonanno, A. Ferro, L.C. Bao, G.M. Marinato, A. Padovan, E. Zulato, S. Frega, A. Dal Maso, G. Pasello, S. Indraccolo, V. Guarneri
Journal: Annals of Oncology (2023)
1230P hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Authors: P. Hofman, A. Prieur, B. Vire, L.F-G. Payen, V. Hofman, C.H. Marquette, J-P. Berthet, J. Boutros, M. Ilie, N. Mimoun, D. Joubert
Journal: Annals of Oncology (2023)
854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
Authors: J. Fayette, L.F.L. Licitra, K.J. Harrington, R. Haddad, L.L. Siu, Y.C. Liu, M. Tahara, J-P. Machiels, D. Rischin, T. Seiwert, R. Ferris, U. Keilholz, A. Psyrri, B. Keam, P. Bossi, R. Metcalf, O. Serrano, P. Kaur, D. Ruscica, R.B. Cohen
Journal: Annals of Oncology (2023)
857O MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)
Authors: P. Blanchard, M. Cheugoua-Zanetsie, I. Deneche, D.I. Rosenthal, M. Gillison, J.G. Eriksen, K. Prabhash, J. Giralt, J.A. Bonner, M.G. Ghi, H. Mehanna, L.L. Siu, M. Gebre Medhin, D. Rischin, A. Dietz, R. Mesia Nin, Y. Pointreau, T. Crombet, A. Auperin
Journal: Annals of Oncology (2023)
1410P Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Authors: N. Reguart Aransay, J. Sánchez, O.J. Juan Vidal, M. Aguilo Domingo, E. Arriola, C. López, X. Botella, F. Cots, C. Montironi, S. Palanca, E. Borràs, L. Masfarre Pinto, L. Planellas, A. Lloansi Vila
Journal: Annals of Oncology (2023)
1242P Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Authors: D. Schaffrin-Nabe, A. Josten-Nabe, S. Schuster, D. Reismann, F. Melchior, D.S. Patil, M. Schaffrin, R. Grünwald, R. Voigtmann
Journal: Annals of Oncology (2023)
868P A DNA methylation classifier to predict recurrence from clear surgical margins
Authors: T. Abou Kors, E. Chteinberg, O. Ammerpohl, R. Siebert, A. Fehn, J. Benckendorff, B.P. SorRoche, F.R. Talukdar, Z. Herceg, L. Arantes, T.F.E. Barth, J. Thomas, J.M. Kraus, J. Ezić, A. von Witzleben, C. Brunner, T.K. Hoffmann, C.H.H. Ottensmeier, H.A. Kestler, S. Laban
Journal: Annals of Oncology (2023)
1224P Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Authors: Y. Nakamura, T. Tin, S. Krinshpun, B. Mitchell, S.L. Bristow, A. Aleshin, M.J.M. Magbanua, L.J. Van't Veer, J. Chapman, C. Lindbjerg Andersen, D.S.W. Tan, T. Yoshino
Journal: Annals of Oncology (2023)
819TiP FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours
Authors: F. Meric-Bernstam, M. Song, S.N. Westin, G. Au-Yeung, P. Mitchell, C. Myers, M. Gymnopoulos, P.G. Fraenkel, M. Nawinne, T. Brier, L. Mileshkin
Journal: Annals of Oncology (2023)
1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Authors: J. Bar, M.H. Cai, Y.C. Choi, S. Baijal, W. Zhao, A. Liede, L. Raskin, A. Vasilopoulos, M. Li, L. Roberts-Rapp, F. Jiang, C. Ratajczak, S. Lu, P.J. Ansell, D.R. Camidge
Journal: Annals of Oncology (2023)
782P Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Authors: D. Netto, X. Wang, B. Barnes, A.R. Clamp, J. Hasan, C.L. Mitchell, Z. Salih, B. Winter-Roach, R. Edmondson, J. Shaw, S. Desai, H. Schlecht, G.J. Burghel, S. Taylor, G. Evans, G.C. Jayson, R.D. Morgan
Journal: Annals of Oncology (2023)
1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Authors: J.C-H. Yang, M. Wang, C-H. Chiu, P-C. Hsu, P. Mitchell, C.L. Chang, T.M. Kim, T. John, L. Greillier, L. Bazhenova, E. Carcereny, A.I. Spira, B. Shim, K.H. Lee, M. Cobo Dols, F. Ghiringhelli, C.W. Yip, J. Xiong, P.A. Jänne, C. Zhou
Journal: Annals of Oncology (2023)
1252P Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Authors: D. Keizer, E. Niemela, Y. Wesseling Rozendaal, S. Karjalainen, E. den Biezen, A. Van Brussel, M.V.J. Mustonen, K. Peltola
Journal: Annals of Oncology (2023)
1212P Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Authors: J. Zhao, Y. Zhang, W. Hu, Y. Du, X. Zhang, N. Ma, W. Yang, Y. Gao, M. Wang, H. Wang, T. Feng, L. Cai, W. Li, F. Su, J. Lu
Journal: Annals of Oncology (2023)
790P Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Authors: B. Corr, J. Hu, C. Walsh, J. Alldredge, L. Brubaker, S. Guntupalli, K. Behbakht, C. Lefkowits, C. Fisher, D. Spinosa, H. Porragas-Paseiro, D. Pino, L. Smith, A. Guimaraes-Young, K. Davies, D. Aisner, R. Wolsky
Journal: Annals of Oncology (2023)
1213P HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Authors: X. Ye, U. Singh, P. Cheng, Y. Guo, J. Wang, K. Bell, K. Urtishak, L. Luo, X. Lyu, W. Xu, Z. Huang, X. Chen, S. Liu, S. Yang, W. Shi, M. Gormley, D.A. Smirnov, L. Zhou, C. Zhu
Journal: Annals of Oncology (2023)
1250P Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Authors: S. Ayyachamy, G. Srinivasan, G. Nandakumar, A. Perumalla, N. Thomas, P. Priya Vijayakumaran, H. Kim, D. Jawahar, N. Duraisamy
Journal: Annals of Oncology (2023)
1401P Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Authors: Q. Thomas, P. Lemercier, G. Justeau, S. Schneider, T. Filleron, J. Remon Masip, M. Pérol, N. Girard, D. Debieuvre, C. Audigier Valette, C. Chouaid, A. Loeb, S. Hiret, C. Clément-Duchêne, E. Dansin, A.T. Stancu, P. Dubray-Longeras, E. Pichon, L. Bosquet, X. Quantin
Journal: Annals of Oncology (2023)
1409P DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Authors: H-S. Li, H. Xu, J. Duan, Z. Wang, J. Zhong, Y-Y. Cui, Q. Fang, S-Y. Lei, Y. Wang
Journal: Annals of Oncology (2023)
1390P Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Authors: P. Christopoulos, N. Girard, L. Zhang, Z. Mbanya, K. Dunton, A. Ali, M. Berktas, L. Delmastro, A. Struebing, Y. Xiong, S. Lay-Flurrie, P. Hindocha, T. Mehdikhanova
Journal: Annals of Oncology (2023)
1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
Authors: S.M. Gadgeel, Q. Zhang, H. Lin, O. Fajardo, H. Trinh, S. Arndorfer, S. Kong, A. Rahman, S. Li, V.R. Archer, J.F. Gainor
Journal: Annals of Oncology (2023)
1239P NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Authors: C. Swanton, V. Bachtiar, C. Mathews, A.R. Brentnall, I. Lowenhoff, J. Waller, M. Bomb, S. McPhail, H. Pinches, R. Smittenaar, S. Hiom, R.D. Neal, P. Sasieni
Journal: Annals of Oncology (2023)
1225P Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Authors: T. Ibrahim, T. Assi, R. Ibrahim, R. Khoury, K. Saleh, C. Chahine, M. Baz, A. Le Cesne
Journal: Annals of Oncology (2023)
1221P The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Authors: L. Incorvaia, C. Marchetti, C. Brando, A. Perez, M. Bono, N. Barraco, D. Cancelliere, A. Pivetti, F. Cardone, T.D. Bazan Russo, L. Castellana, L. Congedo, P. Piraino, R. Ergasti, V. Gristina, A. Galvano, D. Fanale, V. Bazan, G. Scambia, A. Russo
Journal: Annals of Oncology (2023)
1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Authors: L. Paz-Ares, M-J. Ahn, A.E. Lisberg, S. Kitazono, B.C. Cho, G. Blumenschein, E. Shum, E. Pons-Tostivint, Y. Goto, K. Yoh, R. Heist, P. Baas, D. Planchard, M. Pérol, E. Felip, W-C. Su, H. Zebger-Gong, L. Lan, C. Liu, J. Sands
Journal: Annals of Oncology (2023)
1394P Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Authors: U. Janzic, W. Shalata, A. Agbarya, R. Dziadziuszko, K. Szymczak, M. Jakopovic, G. Mountzios, A. Pluzanski
Journal: Annals of Oncology (2023)
860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma
Authors: F. Han, None F. wang, Y-R. Shi, Y. Guo, None X-L. shu, S. Pan, S-H. Qu, P. Zhang, Y. Jiang, M-J. Xu, K. Lei, S. Qu, F. Lei, X. Lv, Y-Q. Xiang, R-H. Xu
Journal: Annals of Oncology (2023)
1386P Validation of MET amplification using next-generation sequencing in lung adenocarcinoma
Authors: M. Salido, S. Clavé, I. Sánchez, P. Rocha, L. Masfarre Pinto, N. Navarro Gorro, M.A. Galindo Campos, R. Del Rey-Vergara, A. Taus Garcia, B. Espinet, E. Arriola, B. Bellosillo Paricio
Journal: Annals of Oncology (2023)
1244P AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Authors: R. Erber, R. Banisch, C. Schaaf, N. Abele, F. Keil, J. James, P. Maxwell, M. Päpper, P. Frey, K. Daifalla, S. Günther, A. Hartmann, T. Lang
Journal: Annals of Oncology (2023)
1416P Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Authors: M.V. Sanchez Becerra, M. Tagliamento, M. Aldea, J. Remon Masip, A. Gazzah, D. Vasseur, P. Lavaud, M. Frelaut, P. Abdayem, M-L. Meyer, M.R. Ghigna, A. Levy, A. Botticella, S. Ponce Aix, F. Barlesi, D. Planchard, B. Besse
Journal: Annals of Oncology (2023)
409P Treatment of elderly patients (pts; &gt; 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Authors: T. Decker, C. Brucker, P. Fasching, T. Göhler, C. Jackisch, J. Janssen, A. Koehler, K. Luedtke-Heckenkamp, None D. Lüftner, M. Van Mackelenbergh, F. Marmé, A. Nusch, B. Rautenberg, T. Reimer, M. Schmidt, R. Weide, P. Wimberger, S. Maslanka Figueroa, C. Roos, A. Woeckel
Journal: Annals of Oncology (2023)
356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Authors: S. Gottipati, H.M. Earl, C. Yau, D.A. Cameron, J. Abraham, L. Hayward, F. Reyal, M. Osdoit, G.S. Sonke, J. Wesseling, J. Boughey, M.P. Goetz, A. DeMichele, L. Pusztai, P. Sharma, M. Martin Jimenez, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, F. Symmans, R. Mukhtar
Journal: Annals of Oncology (2023)
1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Authors: S. Viteri, E. Felip, F. Griesinger, M.C. Garassino, H. Sakai, X. Le, R. Veillon, E.F. Smit, J. Raskin, M. Thomas, M-J. Ahn, S. Vlassak, R. Bruns, A. Johne, P.K. Paik
Journal: Annals of Oncology (2023)
355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Authors: A. DeMichele, E. Price, S. Venters, W. Li, D. Wolf, J. Gibbs, L. Brown-Swigart, M. Klein, N. Onishi, C. Yau, D. Yee, C. Isaacs, J. Perlmutter, H.S. Rugo, L.J. Van't Veer, J. Boughey, F. Symmans, N. Hylton, L. Esserman
Journal: Annals of Oncology (2023)
LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment
Authors: J.W.F. Catto, B. Tran, M. Roupret, J.E. Gschwend, Y. Loriot, H. Nishiyama, J. Palou, S. Daneshmand, S.A. Hussain, H.J. Cutuli, G. Procopio, V. Guadalupi, N. Vasdev, V. Naini, L. Crow, S. Triantos, M. Baig, G.D. Steinberg
Journal: Annals of Oncology (2023)
310P Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Authors: M. Elliott, J. Fuentes Antras, A. Dou, Z.W. Veitch, P.L. Bedard, E. Amir, M. Nadler, E. Van de Laar, C. Yu, M. Annan, A. Silvestro, Q. Zhang, R. Cheikh, J. Kim, O. Barbash, L.L. Siu, H. Berman, D. Cescon
Journal: Annals of Oncology (2023)
LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
Authors: A. Vilaseca, G. Jayram, C. Raventos, N.D. Shore, D. Zainfeld, T.W. Kang, J.H. Ku, J. Meeks, Ó. Rodríguez Faba, F. Roghmann, S. Daneshmand, N. Beeharry, C. Cost, A. Kalota, J. Lauring, M. Peterson, M. Quiroz, N. Stone, W. Zhu, F. Guerrero-Ramos
Journal: Annals of Oncology (2023)
LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy
Authors: A. Necchi, J.M. Jacob, S. Daneshmand, G. Simone, E. Xylinas, D. Morris, P. Spiegelhalder, D. Zainfeld, T.W. Kang, J.T. Matulay, L. Belkoff, K. Decaestecker, H. Arentsen, S. Hampras, C. Cutie, H. Sweiti, K. Stromberg, J. Martin, A. Shukla, M.S. van der Heijden
Journal: Annals of Oncology (2023)
2036P Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Authors: W. Zhang, T. Xu, H. Liu, M. Liu, S. Ying, R. Yuan, H. Zeng, Z. Zhang, S. Han, Z. Si, B. Hu, S. Wen, P. Xu, W. Yu, H. Chen, L. Wang, Z. Lin, T. Dai, Y. Lin
Journal: Annals of Oncology (2023)
728P Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Authors: T. Megid, C.C. Barron, E.F. Saldanha, G.T. Moffat, R. Odwyer, A. Mesci, J. Lukovic, R. Tsang, O. Mete, M.K. Krzyzanowska, L. Ma
Journal: Annals of Oncology (2023)
456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC)
Authors: Y. Eralp, H. Abdel-Razeq, S-A. Im, J. Rihani, Y-S. Lu, Y.S. Yap, H.A. Azim, N. Prasongsook, L. Zhukova, H. Hu, T. Delgar Alfaro, J. Wu, M. Gao, N.S. El Saghir
Journal: Annals of Oncology (2023)
738P Penile squamous cell carcinoma with high and very high tumor mutational burden (TMB): A genomic landscape and "real-world" clinical outcome study
Authors: J.M. Jacob, P. Spiess, T.C.D. Padua, R. Li, P. Grivas, R. Huang, D.I. Lin, N.A. Danziger, J.S. Ross, G. Li, R.P. Graf, D.C. Pavlick, A. Basnet, G. Bratslavsky, A. Necchi
Journal: Annals of Oncology (2023)

TMB is an established biomarker of efficacy with immune-checkpoint inhibitors (ICI) in a pan-cancer indication. TMB, however, has not been specifically considered for penile squamous cell carcinoma (PSCC). We analyzed 397 PSCC cases to identify genomic alterations (GA) in >300 cancer-associated genes, genomic signatures, and TMB using a hybrid capture-based comprehensive genomic profiling (CGP) assay. TMB was categorized as low (<10 mutations [mut]/Mb), high (10-19), and very high (≥20). Tumor cell programmed cell-death ligand-1 (PD-L1) expression was determined by immunohistochemistry (IHC, Dako 22C3) and defined as tumor proportion score (TPS) ≥1%. Germline status of GA was predicted using a validated somatic-germline computational method. Separately, real-world clinical outcomes (RWCOS) data of patients with metastatic penile cancer receiving first-line ICI were obtained from the nationwide (US-based) de-identified Flatiron Health-Foundation Medicine clinico-genomic database (FH-FMI CGDB), which originated from approximately 280 US cancer clinics (∼800 sites of care). There were 339 (85.4%) TMB-low, 40 (10.1%) TMB-high and 18 (4.5%) TMB-very high PSCC. TMB ≥10 vs TMB-low PSCC revealed an enrichment of GA of PIK3CA (48.3% vs 18.3%; p<0.001) and KMT2D (29.3% vs 7.7%; p<0.001), and less frequent GA of CDKN2A (25.9% vs 45.7%, p=0.050). Most of these GA did not co-occur. PD-L1 expression was not impacted by TMB status. HPV identification was more frequent as TMB increased: 28.3% for the TMB-low, 50% for the TMB-high and 58.8% for the TMB-very high groups. In total, 95/1,377 (6.9%) GA were predicted to be of germline nature. In the FH-FMI CGDB cohort, 10 patients receiving ICI, 4 (40%) had a real-world overall survival (rwOS) >12 months with sustained benefit in 3/3 patients with TMB ≥10 mut/Mb. Evaluation of advanced/metastatic PSCC by CGP based on TMB level revealed significant differences in biomarkers for the near 15% of cases that have high and very high TMB ≥10 mut/Mb. These PSCC cases represented a distinct tumor subgroup deserving further clinical investigation.
313P Intrinsic subtypes in a cohort of early breast cancer patients
Authors: T. Bracht, R. Spiller, M. Bauer, S. Kaufhold, V. Hanf, C. Uleer, T. Lantzsch, S. Peschel, J. John, M. Pöhler, E. Weigert, K-F. Bürrig, J. Buchmann, E. Kantelhardt, C. Thomssen, M. Vetter
Journal: Annals of Oncology (2023)